研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[3]Women Hospital, School of Medicine, Zhejiang University[4]Third Military Medical University[5]Beijing Friendship Hospital[6]Sichuan Cancer Hospital and Research Institute[7]Tianjin Medical University[8]West China Second University Hospital[9]Xiangya Hospital of Central South University[10]Qilu Hospital of Shandong University[11]Gansu Cancer Hospital[12]Zhejiang Cancer Hospital[13]Shengjing Hospital[14]Anhui Provincial Cancer Hospital
研究目的：
This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, PFS and OS.
